Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reaffirmed by equities researchers at Goldman Sachs Group Inc. in a research report issued on Tuesday. They presently have a $521.00 price target on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s target price suggests a potential upside of 23.62% from the stock’s current price.
A number of other equities analysts also recently issued reports on REGN. Leerink Swann set a $511.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, August 6th. RBC Capital Markets reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Saturday, August 6th. Cowen and Company reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Monday, June 6th. Robert W. Baird reissued a “neutral” rating and issued a $448.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday. Finally, Piper Jaffray Cos. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Monday, June 6th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $472.46.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 4.29% during midday trading on Tuesday, hitting $421.45. 964,518 shares of the stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $329.09 and a 52 week high of $592.59. The stock has a market capitalization of $44.10 billion, a P/E ratio of 65.75 and a beta of 1.24. The stock’s 50-day moving average price is $405.75 and its 200-day moving average price is $390.36.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.17. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The business’s quarterly revenue was up 21.4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.89 EPS. Equities research analysts expect that Regeneron Pharmaceuticals will post $11.00 EPS for the current fiscal year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the sale, the director now directly owns 15,125 shares of the company’s stock, valued at $6,428,125. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the company. IFP Advisors Inc increased its position in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares in the last quarter. Advisory Services Network LLC increased its position in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares in the last quarter. Fuller & Thaler Asset Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $140,000. Brave Asset Management Inc purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $157,000. Finally, Bessemer Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares in the last quarter. 68.16% of the stock is owned by institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.